Clinical trials: Liraglutide
Obesity
Reward Mechanisms in Obesity
The study aims to investigate the effects of 3.0 mg of liraglutide on reward brain circuits in human obesity and to better understand its effects on weight loss (in patients without diabetes).
- Trial name
- LIRAOB (NCT03347890)
- Where
- Switzerland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Zoltan Pataky
Parkinson Disease
Safety and Efficacy of Liraglutide in Parkinson's Disease
The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
- Trial name
- NCT02953665
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Cedars-Sinai Medical Center
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform…
- Trial name
- ON TARGET DM (NCT05073692)
- Testing
- SU, DPP4, SGLT2i
- Where
- 6 sites in United States
- Volunteers
- 241,981 people
- Sponsor
- Kaiser Permanente
Obesity, Type 2 Diabetes
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
The aim of this study is to investigate if endogenous Glucagon Like Peptide -1 (GLP-1) has an effect on brain satiety and reward systems and if there are alterations in obese patients with type 2 diabetes (T2DM).
- Trial name
- LIBRA (NCT01363609)
- Testing
- Liraglutide treatment 12 weeks, insulin glargine treatment, GLP-1 receptor antagonist
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes Mellitus
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.
- Trial name
- NCT01558271
- Testing
- LY2189265, Liraglutide
- Where
- 14 sites in Japan
- Volunteers
- 492 people
- Sponsor
- Eli Lilly and Company
Osteoarthritis, Obesity
Liraglutide 3 mg for Knee Osteoarthritis
A randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis.
- Trial name
- LOSEIT (NCT02905864)
- Testing
- Liraglutide 3 mg (Saxenda)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Henrik Gudbergsen
Type2Diabetes, ASCVD
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D)…
- Trial name
- PRECIDENTD (NCT05390892)
- Testing
- SGLT2 inhibitor, GLP-1 receptor agonist
- Where
- 36 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Brigham and Women's Hospital
Acute Heart Failure
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical…
- Trial name
- FIGHT (NCT01800968)
- Testing
- Liraglutide
- Where
- 25 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duke University
Obesity & Overweight, Diabetes (DM)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength)…
- Trial name
- NCT07702461
- Testing
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Ohio State University
Monoclonal Gammopathies, Overweight
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.
- Conditions
- Monoclonal Gammopathies, Overweight, Obesity
- Trial name
- NCT02920190
- Testing
- Liraglutide
- Sponsor
- University of Miami
Diabetes, Diabetes Mellitus, Type 1
Liraglutide as add-on to Insulin in Type 1 Diabetes
The purpose of this study is to: Part 1: To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.
- Trial name
- T1DMLIRA (NCT02092896)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
Cushing's Disease, Acromegaly
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
The study was designed to investigate the optimal management of hyperglycemia developed during pasireotide treatment in participants with Cushing's disease or Acromegaly, which was not manageable with metformin.
- Trial name
- NCT02060383
- Testing
- Pasireotide s.c., Sitagliptin, Liraglutide
- Where
- 43 sites in United States, Belgium and 10 more
- Volunteers
- 249 people
- Sponsor
- Novartis Pharmaceuticals
Brain Death
The Use of Liraglutide in Brain Death
There is evidence of the association of brain death and inflammation, affecting outcomes of transplanted organs, but in a way not fully understood.
- Trial name
- NCT03672812
- Testing
- Liraglutide
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ V (NCT01952145)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 91 sites in United States, Argentina and 8 more
- Volunteers
- 557 people
- Sponsor
- Novo Nordisk A/S
Obesity (Disorder), Child Obesity
Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
The aim of the study is to examine the effects of pharmacological treatment for obesity on BMI trajectories and metabolic markers among patients in routine clinical care. A retrospective observational study.
- Trial name
- NCT07304141
- Testing
- Liraglutide 3 mg (Saxenda)
- Where
- Sweden
- Volunteers
- 128 people
- Sponsor
- Göteborg University
Cardiovascular Events, Type2 Diabetes
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose…
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Trial name
- CER-4-T2D (NCT05220917)
- Testing
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA
- Where
- United States
- Volunteers
- 781,430 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
The purpose of this study is to look at the blood sugar control in participants with type 2 diabetes previously treated with premix insulins and initiating treatment with IDegLira.
- Trial name
- GLIDE (NCT05479591)
- Testing
- IDegLira
- Sponsor
- Novo Nordisk A/S
Obesity
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers.
- Trial name
- NCT07640139
- Testing
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Where
- United States
- Volunteers
- 125,000 people
- Sponsor
- Indiana University